- Home
- TBBB vs ACAD Comparison
TBBB vs ACAD Comparison
Compare TBBB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- ACAD
- Stock Information
- Founded
- TBBB 2004
- ACAD 1993
- Country
- TBBB Mexico
- ACAD United States
- Employees
- TBBB N/A
- ACAD N/A
- Industry
- TBBB
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TBBB
- ACAD Health Care
- Exchange
- TBBB NYSE
- ACAD Nasdaq
- Market Cap
- TBBB 2.9B
- ACAD 2.9B
- IPO Year
- TBBB 2024
- ACAD 2004
- Fundamental
- Price
- TBBB $24.52
- ACAD $16.78
- Analyst Decision
- TBBB Hold
- ACAD Buy
- Analyst Count
- TBBB 5
- ACAD 19
- Target Price
- TBBB $32.20
- ACAD $25.33
- AVG Volume (30 Days)
- TBBB 864.5K
- ACAD 1.8M
- Earning Date
- TBBB 03-18-2025
- ACAD 05-07-2025
- Dividend Yield
- TBBB N/A
- ACAD N/A
- EPS Growth
- TBBB N/A
- ACAD N/A
- EPS
- TBBB 0.12
- ACAD 1.36
- Revenue
- TBBB $2,727,305,465.00
- ACAD $957,797,000.00
- Revenue This Year
- TBBB $32.54
- ACAD $13.07
- Revenue Next Year
- TBBB $29.30
- ACAD $9.97
- P/E Ratio
- TBBB $206.24
- ACAD $12.26
- Revenue Growth
- TBBB 29.70
- ACAD 31.85
- 52 Week Low
- TBBB $19.31
- ACAD $14.15
- 52 Week High
- TBBB $35.22
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- ACAD 33.12
- Support Level
- TBBB N/A
- ACAD $17.85
- Resistance Level
- TBBB N/A
- ACAD $19.69
- Average True Range (ATR)
- TBBB 0.00
- ACAD 0.75
- MACD
- TBBB 0.00
- ACAD -0.30
- Stochastic Oscillator
- TBBB 0.00
- ACAD 4.71
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B , Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.